Alamar Biosciences and Partners Launch Major Initiative on Alzheimer's Disease Research

Major Initiative on Alzheimer's Disease Research

Alamar Biosciences, specializing in precision proteomics for early disease detection, has announced a significant global partnership with the Alzheimer's Disease Data Initiative (ADDI) and Gates Ventures. The goal of this collaboration is to develop one of the largest databases of proteomic data linked to clinical outcomes in Alzheimer's disease.

This initiative aims to profile over 40,000 plasma samples that are characteristic of Alzheimer’s disease and related dementias. Utilizing Alamar's ultra-sensitive NULISA™ technology, the project seeks to expedite the discovery of biomarkers and provide new insights into the progression and treatment of this debilitating condition.

Yuling Luo, the founder and CEO of Alamar Biosciences, commented on the collaboration, stating, "This partnership highlights our shared commitment to transforming Alzheimer's disease research through data, technology, and global collaboration." By integrating Alamar's NULISA platform with ADDI's infrastructure and targeted investments from Gates Ventures, they aim to usher in a new era of discovery and therapeutic development based on biomarkers.

The initiative will implement the Alamar NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 across research centers in the United States, Sweden, the United Kingdom, and India. These panels offer unmatched sensitivity and specificity, allowing for precise measurement of hundreds of proteins related to brain and immune system function using minimal amounts of blood or cerebrospinal fluid.

A key feature of the CNS panel is its unique ability to differentiate between phosphorylated tau protein sourced from the brain and the total phosphorylated tau protein content in the blood. This represents a critical advance in developing community screening programs. The generated proteomic data will be integrated with clinical and longitudinal study outcome measurements, subsequently shared with the global research community through secure data-sharing processes established by the Global Neurodegeneration Proteomics Consortium (GNPC).

Niranjan Bose, the CEO for Health and Life Sciences at Gates Ventures and interim executive director of ADDI, underscored the importance of understanding the biological foundations of Alzheimer’s disease, stating, "This project will provide a rich source of information for researchers worldwide and help overcome long-standing barriers to early diagnosis and patient stratification."

This collaboration signifies a substantial advancement in creating a comprehensive, clinically annotated atlas of plasma proteomes in Alzheimer’s disease, with the potential to uncover new biomarkers for diagnosis, prognosis, and therapeutic response. Furthermore, this strategic partnership enhances the efforts of the GNPC, which connects leading researchers and datasets in the field of dementia, jointly aiming to establish one of the largest proteomic datasets dedicated to a specific disease.

The initiative also emphasizes inclusivity by incorporating diverse cohorts from various geographical and ethnic populations, promoting a broadened understanding of Alzheimer’s disease across different demographics.

About the Alzheimer's Disease Data Initiative

The Alzheimer's Disease Data Initiative is a collaborative effort involving prominent academic, advocacy, governmental, industrial, and philanthropic organizations that recognize the need for dementia researchers to find easier ways to share data, analytical tools, and scientific insights. These partners work together to accelerate advancements in new methods for diagnosis, treatment, and drug development for Alzheimer's disease and related dementias. More information can be found at www.alzheimersdata.org.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences company that focuses on precision proteomics to enable the earliest disease detection. Its proprietary NULISA platform and ARGO™ HT system seamlessly integrate with the latest advancements in genomics, achieving detection sensitivities in the attomolar range, significantly surpassing the most sensitive protein detection technologies available today. For more information, visit alamarbio.com.